Two significant positive announcements on Covid-19 vaccine advancements have been released by the American pharmaceutical company Pfizer. On Wednesday, Pfizer Inc said that final results from its Covid-19 vaccine's late-stage trial show that it was 95 percent successful, adding it had the necessary two-month safety data and would apply for US emergency authorization within days.
If the required approvals are obtained, by the end of this year, up to 5 crore doses of the vaccine could be ready and 130 crore doses of the vaccine could be manufactured by the end of next year.
The company which in collaboration with German drugmaker BioNTech SE, develops the Covid-19 vaccine ,It is stated that this vaccine has no serious side effects and has been 94 percent effective in people over the age of 65 years.
"The safety milestone required by the US FDA (Food and Drug Administration) for Emergency Use Authorization (EUA) has been achievedWithin days, we plan to submit a request to the US FDA for an EUA based on the totality of safety and efficacy data collected, as well as manufacturing data relating to the quality and consistency of the vaccine candidate." Pfizer said